Genmab — November 2019
-
kkjoel, det er nøjagtigt den tvivl du nævner, jeg mener vil blive lagt i graven. Der har samlet sig en masse købs interesse omkring Genmab på det sidste, det er min vurdering mange venter på et lille tilbagefald. Jeg tror ikke et fald kommer og køberne vil ende med at presse kursen videre op.
-
-
- (anatomy, medicine) Outside of the bone marrow, as with extramedullary hematopoiesis. [quotations ▼]
2.(anatomy, medicine) Outside of the medulla oblongata, as with extramedullary influences on control of ventilation. [quotations ▼]
3.(anatomy, medicine) Outside of the renal medulla, as with extramedullary electrolytes or renal tissue. [quotations ▼]
4.(anatomy, medicine) Outside of the spinal cord, as with intrameningeal but extramedullary tissues of the central nervous system. [
- (anatomy, medicine) Outside of the bone marrow, as with extramedullary hematopoiesis. [quotations ▼]
-
Nej, 2,5 milestonen skal nok komme - det er $3 mia.-milestonen - i år - man kunne være "bekymret" for. Hvis den ikke når at komme i år ændrer det ikke en tøddel ved Darzas langsigtede potentiale, men de hysteriske kællinger - på markedet og herinde! - vil kalge i flok og løbe forvirrede rundt. DE
TTE.. vil få kursen til at falde
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind